AnteoTech appoints Chief Executive Officer
We are delighted to have partnered with AnteoTech on the appointment of David Radford as CEO.
David is an internationally experienced CEO and Company Director with a track record of identifying and delivering profitable growth across a range of industries and geographies. Most recently, he served as CEO of Australian medical device company AllVascular, which develops and sells patented drug delivery technology with regulatory approval in Europe (CE Mark) and Australia (TGA).
David has built his career through senior executive roles at blue-chip listed companies, ASX listed small caps and private equity-owned businesses including Recall Asia (then part of Brambles Australia), General Electric and Nanosonics Limited (ASX:NAN).
Ewen Crouch, Chair said “The Board is pleased to have secured David Radford as AnteoTech’s CEO. The Board considered that David’s strategic acumen, industry knowledge and high-level C-suite experience made him the standout candidate from a competitive field of applicants following an extensive global search process. As AnteoTech Chairman, I look forward to working with David in guiding the strategic direction of the business as it embarks on commercialising its technologies to underpin an exciting growth phase.”
It was a pleasure working with Ewen Crouch and the broader Board, Geoff Cumming Katherine Woodthorpe AO Chris Parker, and Glenda McLoughlin
Thanks to Ryan Mason, Isabella Polgar, Michael Rewitt & Carmelina Portelli for working with me on this assignment.